ConcertAI LLC, a leading AI and real-world data solutions provider for the life sciences and healthcare sectors, has become a unicorn with its latest Series C funding round of $150 million. This takes its valuation to $1.9 billion in the found spearheaded by Sixth Street. The company was earlier called Concerto HealthAI and it retails AI-based products and healthcare-related data for those providers looking for regulatory clearances or seeking to maintain the same. Its customers also include researchers who are developing clinical trials along with healthcare entities that are seeking enhancement of experiences for patients while also adhering to therapy-related guidelines with a firm emphasis on oncology.

ConcertAI is within SymphonyAI LLC, a bigger AI-based entity that functions in the finance and retail segments. Jeff Elton, the Chief Executive, ConcertAI, stated that the company has attained market leadership and scaled up biomedical and other innovations with its AI-backed software-as-a-service solutions for clinical trials, enhancing patient outcomes for providers. This is ensured by generating evidence that may help peer-review-linked publications, regulatory decisions and clinical interpretations alike.

Elton has also stated that the company’s offerings now cover the whole therapeutics lifecycle with data-as-a-service and also AI-SaaS services for the biopharma space along with the TeraRecon services for backing clinical decision-making. ConcertAI has scaled up its partnerships and customer base to 45+ entities and other organizations in the contract research and life sciences category while claiming to have backed 40+ new launches of products, enhanced therapy timelines by 10%, and lowered the execution of the clinical projects and study design timelines by up to 25%.

Janssen Global Services is one of the foremost partners at ConcertAI and it is the parent entity of Janssen Pharmaceuticals. They tied up for a collaboration focusing on cancer, beginning from early in 2020 and have also expanded ever since to enhance study design and also diversified their clinical trials. Other partners include biopharma company Bristol-Myers Squibb Co. and pharmaceutical behemoth Pfizer Inc. ConcertAI is also partnering with the laboratory testing behemoth Laboratory Corp owned by America Holdings (Labcorp) with regard to studies on precision oncology and an emphasis on enhancing clinical trial access for patients and also patient retention. ConcertAI also confirmed a research agreement for five years with the U.S. FDA (Food & Drug Administration) for the study of new treatments for cancer. ConcertAI Executive Chairman, Romesh Wadhwani has stated that the company is a market leader in the real-world data and enterprise-AI segments of the healthcare and life sciences sectors. He stated that the strong team and leadership at ConcertAI along with 1,000 employees and their cumulative expertise and subject knowledge will propel the company towards greater heights in the future. He also added that the Series C funding by Sixth Street emphasizes upon the links between technology and healthcare while offering more validation of the company’s strategies, customer base, and overall performance.